David Grayzel, a Partner at Atlas Venture, invests primarily in early-stage biotech (seed to Series A) focusing. See sector focus and contact routes.
David Grayzel, a Partner at Atlas Venture, invests primarily in **early-stage biotech** (seed to Series A) focusing on **novel therapeutics**, especially those nearing **first-in-human clinical testing** in areas like **oncology, autoimmunity, and immunology**[1][3][4]. He is distinctive for his **physician-turned-VC thesis** of **co-founding and often serving as CEO** of the companies he backs, rather than acting solely as an investor[2][6]. Notable portfolio companies include **Surface Oncology, Q32 Bio, Comanche Biopharma, Arteaus Therapeutics** (acquired by Eli Lilly), and **Annovation Biopharma** (acquired by The Medicines Company)[1][2][4]. His typical investment range is **$500K–$5.0M**, with a sweet spot around **$2.0M**[5].
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Boston.
Investors like David Grayzel · Full investor directory · Investor access · Company funding database